New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
09:12 EDTNUVANuVasive upgraded to Buy from Neutral at Summer Street
Summer Street upgraded NuVasive to Buy with a $42 price target citing improving spine market conditions following the company's "strong" quarter.
News For NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 12, 2015
07:01 EDTNUVANuVasive receives FDA clearance for X-Core Mini Cervical Corpectomy System
NuVasive announced today the first ever FDA 510(k) clearance of a cervical corpectomy cage. The X-Core Mini Cervical Corpectomy System is an expandable titanium vertebral body replacement device designed to provide enhanced stability following a corpectomy procedure. This first-of-its kind clearance further showcases NuVasive's commitment to investing in innovative technology and clinical research to improve patient outcomes. The NuVasive X-Core Mini Cervical Expandable VBR System is a vertebral body replacement device indicated for use in the cervical spine in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture or osteomyelitis, in addition to the reconstruction following a corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders. X-Core Mini VBR is intended to be used with supplemental fixation cleared by the FDA for use in the cervical spine. These implants are intended for use with autograft or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft, as an adjunct to fusion. It is also intended to restore the integrity of the spinal column even in the absence of fusion for a limited time period in patients with advanced stage tumors involving the cervical spine in whom life expectancy is of insufficient duration to permit achievement of fusion, with bone graft used at the surgeon's discretion.
October 9, 2015
11:25 EDTNUVASpinal device makers slump after LDR revenue warning
Shares of LDR Holding (LDRH) plunged in morning trading after the medical device company reported lower than expected preliminary revenue for the third quarter. Notably, however, LDR reaffirmed its anticipated revenue growth for fiscal 2015. WHAT'S NEW: After the market close yesterday, LDR said it expects to report Q3 revenue of roughly $39.3M, which would fall short of the consensus estimate of $40.2M. The company also backed its expected revenue growth guidance for FY15 of 19%-20%, implying revenues of $168.1M-$169.5M, excluding the impact of foreign exchange, which the company sees having a negative impact of 4%-5%. Analysts currently expect FY15 revenue of $164.3M. LDR Holding is scheduled to report complete Q3 earnings after the market close on Wednesday, November 4. WHAT'S NOTABLE: Christophe Lavigne, president and chief executive officer of LDR, said that seasonality was "more pronounced" in Q3 than in the prior year, and that any seasonality impact in 3Q14 was "muted" since it was the first full year of the company's commercial launch of Mobi-C in the U.S. STREET RESEARCH: Commenting on the company's preliminary Q3 revenue report, Northland analyst Mark Landy said that LDR is not a proxy for the broader spine market and that the "vast majority" of the firm's revenues are from niche products. The analyst said that LDR's news should not be extrapolated to rivals NuVasive (NUVA) and K2M Group (KTWO). Landy added that analyst expectations for Mobi-C growth in 2015 might have been "a touch" optimistic amid a slower than expected broadening of reimbursement for two-level use. The analyst maintained an Outperform rating and a $38 price target on LDR stock. Piper Jaffray analyst Matt O'Brien kept an Overweight rating but decreased the price target for LDR's shares to $37.50 from $45, adding that his checks indicate increased interest in and adoption of Mobi-C and that he continues to be optimistic in the company's growth prospects. RBC Capital analyst Brandon Henry maintained an Outperform rating on LDR's stock, yet lowered the price target to $33 from $50, citing recent market volatility and his firm's own reduced revenue expectations. The analyst said he remains positive in the Mobi-C technology as well as the multi-year growth opportunity in the U.S. cervical artificial disk market. Cowen analyst Joshua Jennings said that LDR's weaker than expected third quarter revenue indicate a "small bump in the road" and will ultimately provide a buying opportunity in the company's shares. The analyst said that more pronounced seasonality had a negative impact on the revenue miss as well as tough comps, but LDR's fundamentals remain intact as the Mobi-C opportunity is in the "very early innings." Jennings affirmed an Outperform rating and a $55 price target on LDR Holding shares. PRICE ACTION: In morning trading, LDR Holding shares dropped 24.7% to $27.27, NuVasive fell 1.2% and K2M Group slumped 6.8% to $17.78.
08:48 EDTNUVAInvestors should look at several medtech stocks, says BMO Capital
BMO Capital believes that macro issues have caused declines in medtech stocks. However, the firm thinks that the sector dealt with pricing issues years ago, while patient volumes are rising and larger cap names in the sector have "relatively stable revenue streams." BMO recommends that investors look at stocks with "reasonable multiples," such as Medtronic (MDT), those with new product pipelines such as Boston Scientific (BSX) and Edwards Lifesciences (EW), and those with small-cap product cycles, including Nevro (NVRO), NuVasive (NUVA), and Endologix (ELGX).
06:53 EDTNUVALDR Holding not a proxy for broader spine market, says Northland
After the company preannounced Q3 revenue that came in slightly below the consensus, Northland analyst Mark Landy says LDR Holding (LDRH) is a not a proxy for the broader spine market. The vast majority of LDR's sales are from niche products, Landy tells investors in a research note. As such, he believes last night's news should not be extrapolated to NuVasive (NUVA) and K2M Group (KTWO). He thinks the consensus estimates for LDR's MOBI-C growth in 2015 may have been a "touch optimistic" given a slower than expected broadening of reimbursement for two-level use. He keeps an Outperform rating on LDR Holding with a $38 price target.
October 7, 2015
11:32 EDTNUVALeerink medical supplies/devices analyst holds analyst/industry conference call
Subscribe for More Information
October 6, 2015
10:00 EDTNUVAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Communications Sales & Leasing (CSAL) upgraded to Overweight at Morgan Stanley... FedEx (FDX) upgraded on upcoming positive catalysts at Stifel... Mediaset (MDIUY) upgraded to Buy from Hold at HSBC... Melco Crown (MPEL) upgraded to Hold from Sell at Deutsche Bank... NuVasive (NUVA) upgraded to Buy at Canaccord... SJM Holdings (SJMHY) upgraded to Hold from Sell at Deutsche Bank... Select Medical (SEM) upgraded on expected EBITDA jump at Wells Fargo... Smart & Final Stores (SFS) upgraded to Overweight from Equal Weight at Barclays... Springleaf (LEAF) upgraded to Outperform from Market Perform at Keefe Bruyette... Tanger Factory (SKT) upgraded to Neutral from Underperform at BofA/Merrill.
07:55 EDTNUVANuVasive upgraded to Buy at Canaccord
As reported previously, Canaccord upgraded NuVasive to Buy from Hold as they believe a current and projected strong U.S. macro environment for the broad spine market offsets tough comps and will continue to provide a solid tailwind. The firm also sees continued margin expansion and integration of its iGA platform strategy. Canaccord raised its price target to $58 from $52 on NuVasive shares.
06:08 EDTNUVANuVasive upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information
06:07 EDTNUVANuVasive upgraded to Buy from Hold at Canaccord

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use